About Aurum Ventures MKI
Aurum Ventures MKI is the private investment vehicle of Morris Kahn, operating from Ramat Gan in Israel as a family office rather than a traditional fund. The vehicle backs surgical visualization and targeted drug delivery startups, with the family-office structure providing flexibility that fixed-fund VCs often cannot match, including longer hold periods and the ability to support follow-on rounds without standard fund-life pressure.
Stages listed are Series A and Series B, with check sizes between $1 million and $5 million. Sub-verticals are medical devices and biotech. The record does not list specific portfolio companies, but the surgical visualization and drug delivery focus suggests a preference for clinically validated platforms over pure-software or population-health products. Geographic activity is concentrated in Israel.
For founders, the practical implication of family-office capital is a different relationship cadence than a standard VC. Decisions can be faster when the principal is engaged but slower when not, and there is typically less of a fund-life pressure to push exits. Surgical visualization, image-guided intervention, and targeted drug delivery teams will find the clearest fit. Pure healthcare AI software founders should expect the conversation to focus on clinical validation and integration with hardware platforms rather than ARR or software KPIs. Strong Israeli clinical site partnerships are a meaningful asset in this conversation.
Founder reviews
Other portfolio companies
Companies in Aurum Ventures MKI's portfolio not currently in our directory.
Pitch / review this investor
Have you raised from Aurum Ventures MKI? Founders only — share your honest experience (anonymous OK, moderated before publishing).